Tower Place, 1 Tower Pl, South San Francisco, CA 94080
As a leading biotech company dedicated to advancing drug development with innovative mouse models to accelerate drug discovery, Biocytogen is hosting a symposium for the biotech and biopharma industry on September 25th in South San Francisco from 4:00 pm to 8:00 pm.
It is our great honor to invite you to speak at our Bay Area Biotech/Biopharma Workshop with the topic Robust in vivo models derisk clinical trials.
Theme: Robust in vivo models derisk clinical trials
4:00-4:30pm Registration
4:30-4:40pm Opening remark, James Jin, VP at Biocytogen.
Topic: Translational in vivo studies catalyzing clinical trials of Azelaprag
Yan Wang, Ph.D VP, Translational Aging Biology, BioAge Labs
Topic: Conditional deletion of Neurexin-2 leads to spontaneous seizures and behavioral inflexibility
Lulu Y. Chen, Ph.D Assistant professor in the Dept of Anatomy and Neurobiology, School of Medicine, University of California, Irvine.
RSVP Now
Spaces are limited, and this is a popular event. Secure your spot today by registering now.
About Biocytogen
Biocytogen is a global biotechnology company focused on the research and development of novel antibody-based drugs. Utilizing proprietary gene-editing technology and the RenMice platforms, Biocytogen drives fully human monoclonal antibody discovery with a library of over 400,000 fully human antibody sequences against nearly 1,000 targets for global partnerships. Biocytogen also provides drug-target knock-in humanized models and off-the-shelf animal and cell models, along with comprehensive preclinical pharmacology and custom gene-editing model services.
.png?width=100&height=100&name=%E5%B7%A5%E4%BD%9C%E5%8D%80%E5%9F%9F%201%20(1).png "工作區域 1 (1)")
